Humoral markers of active Epstein–Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus
Restricted accessResearch articleFirst published online December, 2016
Humoral markers of active Epstein–Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus
We investigated if signs of active Epstein–Barr virus and cytomegalovirus infections associate with certain autoantibodies and a marker of type I interferon activity in patients with systemic lupus erythematosus. IgM and IgG plasma levels against Epstein–Barr virus early antigen diffuse and cytomegalovirus pp52 were applied as humoral markers of ongoing/recently active Epstein–Barr virus and cytomegalovirus infections, respectively. Plasma galectin-3 binding protein served as a surrogate marker of type I interferon activity. The measurements were conducted in 57 systemic lupus erythematosus patients and 29 healthy controls using ELISAs. Regression analyses and univariate comparisons were performed for associative evaluation between virus serology, plasma galectin-3 binding protein and autoantibodies, along with other clinical and demographic parameters. Plasma galectin-3 binding protein concentrations were significantly higher in systemic lupus erythematosus patients (P = 0.009) and associated positively with Epstein–Barr virus early antigen diffuse-directed antibodies and the presence of autoantibodies against extractable nuclear antigens in adjusted linear regressions (B = 2.02 and 2.02, P = 0.02 and P = 0.002, respectively). Furthermore, systemic lupus erythematosus patients with anti-extractable nuclear antigens had significantly higher antibody levels against Epstein–Barr virus early antigen diffuse (P = 0.02). Our study supports a link between active Epstein–Barr virus infections, positivity for anti-extractable nuclear antigens and increased plasma galectin-3 binding protein concentrations/type I interferon activity in systemic lupus erythematosus patients.
RönnblomLPascualV. The innate immune system in SLE: type I interferons and dendritic cells. Lupus2008; 17: 394–399.
2.
YtterbergSRSchnitzerTJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum1982; 25: 401–406.
3.
KimTKanayamaYNegoroNOkamuraMTakedaTInoueT. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol1987; 70: 562–569.
4.
BaechlerECBatliwallaFMKarypisGGaffneyPMOrtmannWAEspeKJ. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA2003; 100: 2610–2615.
5.
Lyn-CookBDXieCOatesJTreadwellEWordBHammonsG. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol Immunol2014; 61: 38–43.
6.
HooksJJMoutsopoulosHMGeisSAStahlNIDeckerJLNotkinsAL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med1979; 301: 5–8.
7.
BengtssonAASturfeltGTruedssonLBlombergJAlmGVallinH. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus2000; 9: 664–671.
8.
KirouKALeeCGeorgeSLoucaKPetersonMGCrowMK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum2005; 52: 1491–1503.
9.
HuaJKirouKLeeCCrowMK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum2006; 54: 1906–1916.
10.
FarkasATonelGNestleFO. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol2008; 158: 921–929.
11.
BlancoPPaluckaAKGillMPascualVBanchereauJ. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science2001; 294: 1540–1543.
12.
YanBYeSChenGKuangMShenNChenS. Dysfunctional CD4+,CD25+regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum2008; 58: 801–812.
13.
BåveUMagnussonMElorantaMLPerersAAlmGVRönnblomL. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol2003; 171: 3296–3302.
14.
LövgrenTElorantaMLBåveUAlmGVRönnblomL. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum2004; 50: 1861–1872.
15.
BåveUAlmGVRönnblomL. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol2000; 165: 3519–3526.
16.
LövgrenTElorantaMLKastnerBWahren-HerleniusMAlmGVRönnblomL. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren’s syndrome autoantigen-associated RNA. Arthritis Rheum2006; 54: 1917–1927.
17.
WeckerleCEFranekBSKellyJAKumabeMMikolaitisRAGreenSL. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum2011; 63: 1044–1053.
18.
McClainMTHeinlenLDDennisGJRoebuckJHarleyJBJamesJA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med2005; 11: 85–89.
19.
JamesJAScofieldRHHarleyJB. Lupus humoral autoimmunity after short peptide immunization. Ann NY Acad Sci1997; 815: 124–127.
20.
PooleBDGrossTMaierSHarleyJBJamesJA. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun2008; 31: 362–371.
21.
Zandman-GoddardGBerkunYBarzilaiOBoazMBlankMRamM. Exposure to Epstein–Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci2009; 1173: 658–663.
22.
EsenBAYılmazGUzunSOzdamarMAksözekAKamalıS. Serologic response to Epstein–Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int2012; 32: 79–83.
23.
De PaschaleMCagninDCerulliTMancoMTAgrappiCMirriP. Search for anti-EA(D) antibodies in subjects with an “isolated VCA IgG” pattern. Int J Microbiol2010; 2010: 695104–695104.
24.
OokaTTurenne-TessierMDStolzenbergMC. Relationship between antibody production to Epstein–Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol1991; 13: 233–247.
25.
QuanTERomanRMRudengaBJHolersVMCraftJE. Epstein–Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum2010; 62: 1693–1701.
26.
SeveraMGiacominiEGafaVAnastasiadouERizzoFCorazzariM. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol2013; 43: 147–158.
27.
RasmussenNSDraborgAHNielsenCTJacobsenSHouenG. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol2015; 44: 143–149.
28.
StrattaPCanaveseCCicconeGSantiSQuagliaMGhisettiV. Correlation between cytomegalovirus infection and Raynaud’s phenomenon in lupus nephritis. Nephron1999; 82: 145–154.
29.
HugginsMLToddIPowellRJ. Reactivation of Epstein–Barr virus in patients with systemic lupus erythematosus. Rheumatol Int2005; 25: 183–187.
BroccoloFDragoFCassinaGFavaAFusettiLMatteoliB. Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. J Med Virol2013; 85: 1925–1934.
32.
LarsenMSauceDDebackCArnaudLMathianAMiyaraM. Exhausted cytotoxic control of Epstein–Barr virus in human lupus. PLoS Pathog2011; 7: 1371–1371.
33.
DraborgAHJacobsenSWestergaardMMortensenSLarsenJLHouenG. Reduced response to Epstein–Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med2014; 1: 1136–1136.
34.
KangIQuanTNolascoHParkSHHongMSCrouchJ. Defective control of latent Epstein–Barr virus infection in systemic lupus erythematosus. J Immunol2004; 172: 1287–1294.
35.
SchneiderKMeyer-KoenigUHufertFT. Human cytomegalovirus impairs the function of plasmacytoid dendritic cells in lymphoid organs. PLoS One2008; 3: 3482–3482.
36.
ChangWLWBarryPASzubinRWangDBaumgarthN. Human cytomegalovirus suppresses type 1 interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology2009; 390: 330–337.
37.
Palafox SánchezCASatohMChanEKCarcamoWCMuñoz ValleJFOrozco BarocioG. Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies. Arthritis Res Ther2009; 11: R27–R27.
38.
NielsenCTLoodCØstergaardOIversenLVVossABengtssonA. Plasma levels of galectin-3 binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med2014; 1: 1136–1136.
39.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
40.
PetriMKimMYKalunianKCGrossmanJHahnBHSammaritanoLR. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558.
41.
Høier-MadsenMNielsenLPMøllerS. Determination of IgM rheumatoid factor by enzyme-linked immunosorbent assay (ELISA). Dan Med Bull1986; 148: 2018–2021.
42.
SvendsenAJHjelmborgJVKyvikKOHouenGNielsenCSkyttheAJunkerP. The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs. J Autoimmun2013; 41: 120–125.
43.
MacbethGRazumiejczykELedesmaDR. Cliff’s delta calculator: a non-parametric effect size program for two groups of observations. Univ Psychol2011; 10: 545–555.
44.
MathianAAmouraZAdamEColaoneFHoekmanMFDhellinO. Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Ann Rheum Dis2011; 70: 1138–1143.
PetriMWallaceDJSpindlerAChindaloreVKalunianKMyslerE. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum2013; 65: 1011–1021.
DrorYBlacharYCohenPLivniNRosenmannEAshkenaziA. Systemic lupus erythematosus associated with acute Epstein–Barr virus infection. Am J Kidney Dis1998; 32: 825–828.
49.
BhimmaRAdhikariMCoovadiaHM. Epstein–Barr virus-induced systemic lupus erythematosus. S Afr Med J1995; 85: 899–900.
50.
GrassadoniaATinariNFiorentinoBSuzukiKNakazatoMDe TursiM. The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. Endocrinology2004; 145: 4728–4736.
51.
ShakedIHannaDBGleissnerCMarshBPlantsJTracyD. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol2014; 34: 1085–1092.
